AbbVie Must Be Sent Message, Jury Told In AndroGel Trial

By Diana Novak Jones (March 22, 2018, 8:21 PM EDT) -- Attorneys for a man who suffered a heart attack while on AbbVie's AndroGel wrapped up their case Thursday, telling an Illinois federal jury that the pharmaceutical company won't change the way it sells its blockbuster testosterone replacement therapy drug unless it is sent a strong message and faces financial pressure....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!